You are here

  • Home
  • Archive
  • Volume 10, Issue Suppl 2
  • 627 Oral administration of MRx0518 in treatment-naïve cancer patients is associated with compositional taxonomic and metabolomic changes indicative of anti-tumorigenic efficacy

Share

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Clinical Trials In Progress
627 Oral administration of MRx0518 in treatment-naïve cancer patients is associated with compositional taxonomic and metabolomic changes indicative of anti-tumorigenic efficacy
Free

Share this article

Click the icon of the social media platform on which you would like to share this article.

Twitter logo Facebook logo LinkedIn logo

Email this article to a friend

We will not keep your email address; we ask for it so your friend knows the email isn't spam.
Enter multiple addresses on separate lines or separate them with commas.
627 Oral administration of MRx0518 in treatment-naïve cancer patients is associated with compositional taxonomic and metabolomic changes indicative of anti-tumorigenic efficacy
(Your Name) has forwarded a page to you from Journal for ImmunoTherapy of Cancer
(Your Name) thought you would like to see this page from the Journal for ImmunoTherapy of Cancer web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.